TCP
CHRS icon

Tourbillon Capital Partners’s Coherus Oncology CHRS Stock Holding History

Tourbillon Capital Partners’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-784,176
Closed -$15.7M – 81
2015
Q3 		$15.7M Buy
784,176
+19,176
+3% +$584K 0.41% 55
2015
Q2 		$22.1M Buy
765,000
+715,000
+1,430% +$18.1M 0.48% 60
2015
Q1 		$1.53M Buy
+50,000
New +$1.29M 0.04% 73

Other funds holding CHRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Tourbillon Capital Partners's CHRS Position: Q4 2015 in Review

Tourbillon Capital Partners sold out of Coherus Oncology (CHRS) in Q4 2015, closing a stake of 784,176 shares — an estimated $15.7M sold.

Tourbillon Capital Partners first reported a position in CHRS in Q1 2015 and held it in 3 quarters. The position peaked at $22.1M in Q2 2015. 77 funds tracked by Wall St. Rank hold CHRS as of Q4 2015.

  • Tourbillon Capital Partners reported no remaining Coherus Oncology position as of Q4 2015 after selling out during the quarter.
  • Tourbillon Capital Partners sold 784,176 Coherus Oncology shares in Q4 2015, an estimated $15.7M.
  • Tourbillon Capital Partners first reported a position in Coherus Oncology in Q1 2015 and held it in 3 quarters.
  • Tourbillon Capital Partners's Coherus Oncology position peaked at $22.1M in Q2 2015.
  • 77 funds tracked by Wall St. Rank held Coherus Oncology as of Q4 2015.

Based on Tourbillon Capital Partners's 13F filing for Q4 2015, filed 16 Feb 2016.